Therapy Optimisation for the Treatment of Hairy Cell Leukemia

Status Recruiting

Clinical Trial Summary

The trial will test the effectiveness and toxicity of subcutaneous treatment with one cycle of cladribine in patients with hairy cell leukemia requiring treatment. They have to be untreated so far or may be pretreated with alpha-interferon.

Clinical Trial Description

Evaluation of remission status will take place 4 months after treatment. In addition, it will be tested whether patients with non-optimal response will have a benefit from a second cycle of cladribine. Non-optimal response is: patients with detectable residual disease; achievement of partial remission or detectable residual infiltration in the bone marrow. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02131753
Study type	Interventional
Source	University of Giessen
Contact	Mathias J Rummel, Prof PhD
Phone	+4964198542
Email	mathias.rummel@innere.med.uni-giessen.de
Status	Recruiting
Phase	Phase 2/Phase 3
Start date	May 2004
Completion date	December 2027

View Details

See also
Status	Clinical Trial	Phase
Enrolling by invitation	`NCT05645744` - Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product.
Active, not recruiting	`NCT03805932` - Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia	Phase 1
Recruiting	`NCT04324112` - Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCL	Phase 2
Active, not recruiting	`NCT01711632` - BRAF Inhibitor, Vemurafenib, in Patients With Relapsed or Refractory Hairy Cell Leukemia	Phase 2
Withdrawn	`NCT03739606` - Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer	Phase 2
Active, not recruiting	`NCT00923013` - Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia	Phase 2
Completed	`NCT00898079` - Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer
Completed	`NCT01720758` - Assessment of the V600E Mutation in the B-RAF Gene in Chronic Lymphoproliferative Disease	N/A
Recruiting	`NCT04815356` - Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and Variant	Phase 1
Completed	`NCT00321555` - LMB-2 to Treat Hairy Cell Leukemia	Phase 2
Completed	`NCT00586924` - A Phase I, Multicenter Dose Escalation Study in Patients With Hairy Cell Leukemia	Phase 1
Recruiting	`NCT06340737` - AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas	Phase 1
Recruiting	`NCT05388123` - Low Dose Vemurafenib and Rituximab in Hairy Cell Leukemia	Phase 2
Not yet recruiting	`NCT05859932` - Assessing Medical Trial Experiences of Hairy Cell Leukemia Patients
Recruiting	`NCT04952974` - B-cell Chronic Lymphoid Malignancies Markers
Recruiting	`NCT00412594` - Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia	Phase 2
Recruiting	`NCT04775745` - Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.	Phase 1
Completed	`NCT03010358` - Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma	Phase 1/Phase 2
Active, not recruiting	`NCT01059786` - Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia	Phase 2
Recruiting	`NCT04322383` - Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant	Phase 2